tetano
Editor, Senior Moderator
NPJ Vaccines
. 2024 May 23;9(1):90.
doi: 10.1038/s41541-024-00870-8. Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
Bryce M Warner[SUP] #[/SUP][SUP] 1 [/SUP], Jacob G E Yates[SUP] #[/SUP][SUP] 2 [/SUP], Robert Vendramelli[SUP] 1 [/SUP], Thang Truong[SUP] 1 [/SUP], Courtney Meilleur[SUP] 1 [/SUP], Lily Chan[SUP] 2 [/SUP], Alexander Leacy[SUP] 2 [/SUP], Phuc H Pham[SUP] 2 [/SUP], Yanlong Pei[SUP] 2 [/SUP], Leonardo Susta[SUP] 3 [/SUP], Sarah K Wootton[SUP] 4 [/SUP], Darwyn Kobasa[SUP] 5 6 [/SUP]
Affiliations
The rapid development and deployment of vaccines following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been estimated to have saved millions of lives. Despite their immense success, there remains a need for next-generation vaccination approaches for SARS-CoV-2 and future emerging coronaviruses and other respiratory viruses. Here we utilized a Newcastle Disease virus (NDV) vectored vaccine expressing the ancestral SARS-CoV-2 spike protein in a pre-fusion stabilized chimeric conformation (NDV-PFS). When delivered intranasally, NDV-PFS protected both Syrian hamsters and K18 mice against Delta and Omicron SARS-CoV-2 variants of concern. Additionally, intranasal vaccination induced robust, durable protection that was extended to 6 months post-vaccination. Overall, our data provide evidence that NDV-vectored vaccines represent a viable next-generation mucosal vaccination approach.
. 2024 May 23;9(1):90.
doi: 10.1038/s41541-024-00870-8. Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
Bryce M Warner[SUP] #[/SUP][SUP] 1 [/SUP], Jacob G E Yates[SUP] #[/SUP][SUP] 2 [/SUP], Robert Vendramelli[SUP] 1 [/SUP], Thang Truong[SUP] 1 [/SUP], Courtney Meilleur[SUP] 1 [/SUP], Lily Chan[SUP] 2 [/SUP], Alexander Leacy[SUP] 2 [/SUP], Phuc H Pham[SUP] 2 [/SUP], Yanlong Pei[SUP] 2 [/SUP], Leonardo Susta[SUP] 3 [/SUP], Sarah K Wootton[SUP] 4 [/SUP], Darwyn Kobasa[SUP] 5 6 [/SUP]
Affiliations
- PMID: 38782986
- DOI: 10.1038/s41541-024-00870-8
The rapid development and deployment of vaccines following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been estimated to have saved millions of lives. Despite their immense success, there remains a need for next-generation vaccination approaches for SARS-CoV-2 and future emerging coronaviruses and other respiratory viruses. Here we utilized a Newcastle Disease virus (NDV) vectored vaccine expressing the ancestral SARS-CoV-2 spike protein in a pre-fusion stabilized chimeric conformation (NDV-PFS). When delivered intranasally, NDV-PFS protected both Syrian hamsters and K18 mice against Delta and Omicron SARS-CoV-2 variants of concern. Additionally, intranasal vaccination induced robust, durable protection that was extended to 6 months post-vaccination. Overall, our data provide evidence that NDV-vectored vaccines represent a viable next-generation mucosal vaccination approach.